Chief Business Officer
Ellen Lubman has served as chief business officer of Werewolf Therapeutics since August 2020. Ellen most recently served as the chief business officer at Impel NeuroPharma, a publicly traded biotechnology company focused on neurological diseases. Prior to Impel, she was the vice president of external science and innovation at Forest Labs until its acquisition by Actavis in July 2014, and served in the same role at Actavis through June 2018 during which time Actavis merged with and renamed itself Allergan. Ellen has held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs. She currently serves on the advisory board of TMRW.org, the scientific advisory board of the Daedalus Innovation Fund of Weill-Cornell and the board of directors of Red Door Community of NYC. She is also chairwoman for the Southern California region of Executive Women in BIO. Ellen earned her MBA from Stanford Graduate School of Business with a focus on global management and her B.A. in biology from Rutgers College.